After Hours Summary: COST +2% following earnings, MENT +6% on Elliot active stake news, WMT +0.5% with Costco/analyst initiation... CAMP -13% on earnings/guidance, THLD -70% discontinuing Tarloxotinib Program/cutting staff newsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AEHR +7.4% (light volume), COST +1.7% (also responds to the partial jury verdict returned in the case brought by Tiffany)
Companies trading higher in after hours in reaction to news: AUPH +13.3% (announces that voclosporin achieves primary and all pre-specified secondary endpoints in Phase IIb AURA-LV study for Lupus Nephritis), MENT +5.6% (Elliot Mgmt discloses 8.1% active stake -- has communicated with management and Board about a broad range of operational and strategic matters), OZM +5.1% (confirms reaching settlements w/ the DOJ and the SEC; will pay a total penalty of $412 mln; entered into a securities purchase agreement with certain executive managing directors), CEMP +4.4% (light volume - announces interim results showing anti-NASH effects in the first six nonalcoholic steatohepatitis patients dosed with solithromycin in a Phase 2 study), NVFY +1.2% (to sell NOVA BVI and its subsidiaries for $8.5 mln to Kuka Design), HLIT +1.2% (Comcast confirms 6.6% passive stake -- the cos entered into a warrant agreement this week), ZNGA +1.1% (appoints Gerard Griffin as CFO effective immediately), WMT +0.5% (initiated with an Overweight at KeyBanc Capital Markets; tgt $90), AA +0.5% (approves proposed separation; separation is scheduled to become effective before the opening of the market on November 1, 2016), PSX +0.3% (upgraded to Neutral from Sell at Goldman)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CAMP -12.9%,
Companies trading lower in after hours in reaction to news: THLD -67% (to discontinue investment in its Tarloxotinib Program after interim data; implementing workforce reduction), MIRN -17.1% (Mirna Therapeutics Investigational New Drug for MRX34 has been placed on full clinical hold), ABUS -13.9% (reports interim results from the first two cohorts of the ongoing ARB-1467 Phase II multi-dose clinical trial in chronically infected HBV patients), VNRX -8.5% (announces proposed public offering of common stock), DCTH -5.8% (intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering), STAY -4.6% (commences 13 mln paired shares offering by certain selling stockholders affiliated with Centerbridge Partners, Paulson & Co and The Blackstone Group), IRT -0.9% (prices public offering of 25 mln shares of common stock at $9.00 per share for total gross proceeds of $225.0 mln)